Health Care · Biotechnology

Arcellx ACLX

$115.07+0.02 (+0.02%)cached quote · as of 2026-07-19 00:25 UTC

Open ACLX in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$6.7B

Previous close

$115.05

Volume

—

52-week range

—

Verdictconfidence 58% · moderate

Health and Momentum stand out; growth and quality flash caution.

2 of 5 dimensions score well; growth and quality flash caution. Value not scored — not enough data.

Value—0/2 checks

Growth00/3 checks

Quality251/4 checks

Health1003/3 checks

Momentum1003/3 checks

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

—

EV/EBITDA TTM

—

PEG

—

FCF yield TTM

-3.2%

Growth

Revenue 3y

—

Revenue YoY

−79.4%

Expected EPS

—

Quality

Piotroski F

1 / 9

ROIC

—

Gross margin

—

Health

Altman Z

17.72

Current ratio

4.44

Debt/equity

—

Momentum

vs 50-day

+15.5%

vs 200-day

+42.4%

52-wk range

—

FY 2025: revenue $22.3M · net income -$228.9M · free cash flow -$212.6M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-19 00:25 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading ACLX’s filed statements…

Continue with ACLX in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.